Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data

Bibliography

• Gotto AM Jr, Moon JE. Pharmacotherapies for lipid modification: beyond the statins. Nat Rev Cardiol 2013;10:560-70
   PubMed Web of Science ®Google Scholar
• Catapano AL. Perspectives on low-density lipoprotein cholesterol goal achievement. Curr Med Res Opin 2009;25:431-47
   PubMed Web of Science ®Google Scholar
• Jones P, Nair R, Thakker KM. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc 2012;1:e001800
   Web of Science ®Google Scholar
• Barter P. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Am J Cardiol 2009;104(10 Suppl):10E-5E
   PubMed Web of Science ®Google Scholar
• Maxwell KN, Breslow JL. Adenoviral mediated expression of PCSK9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci USA 2004;101:7100-5
   PubMed Web of Science ®Google Scholar
• Abifadel M, Varret M, Rabee JD, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003;34:154-6
   PubMed Web of Science ®Google Scholar
• Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354:1264-7
   PubMed Web of Science ®Google Scholar
• Cicero AF, Tartagni E, Ertek S. Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence. Expert Opin Biol Ther 2014;6):863-8
   PubMed Web of Science ®Google Scholar
• Farnier M. PCSK9 inhibitors. Curr Opin Lipidol 2013;24:251-8
   PubMed Web of Science ®Google Scholar
• Stein EA, Giugliano RP, Koren MJ, et al. For the PROFICIO Investigators. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J 2014. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Koren MJ, Lundqvist P, Bolognese M, et al. Anti-pcsk9 monotherapy for hypercholesterolemia – the mendel-2 randomized, controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 2014. [ Epub ahead of print]
   Google Scholar
• Stroes E, Colquhoun D, Sullivan D, et al. GAUSS-2 Investigators. Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients with Statin Intolerance: the GAUSS-2 Randomized, Placebo-controlled Phase 3 Clinical Trial of Evolocumab. J Am Coll Cardiol 2014. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Hala T, Bolognese M, Lillestol MJ, et al. the descartes investigators. A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia. N Engl J Med 2014;370(19):1809-19
   PubMed Web of Science ®Google Scholar
• Koren MJ, Giugliano RP, Raal FJ, et al. OSLER Investigators. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation 2014;129(2):234-43
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov/show/NCT01764633 [Last accessed 1 June 2014]
   Google Scholar
• Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012;366:1108-18
   PubMed Web of Science ®Google Scholar
• McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012;59(25):2344-53
   PubMed Web of Science ®Google Scholar
• Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012;380(9836):29-36
   PubMed Web of Science ®Google Scholar
• Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012;367(20):1891-900
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov/show/NCT01507831 [Last accessed 1 June 2014]
   Google Scholar
• Available from: http://www.pmlive.com/pharma_news/fda_scrutiny_of_alirocumab_hits_regeneron_and_sanofi_551477 [Last accessed 1 June 2014]
   Google Scholar
• Yu RZ, Geary RS, Flaim JD, et al. Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2’-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin Pharmacokinet 2009;48(1):39-50
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, Wedel MK, Baker BF, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006;114(16):1729-35
   PubMed Web of Science ®Google Scholar
• Akdim F, Tribble DL, Flaim JD, et al. Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. Eur Heart J 2011;32:2650-9
   PubMed Web of Science ®Google Scholar
• Akdim F, Stroes ES, Sijbrands EJ, et al. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol 2010;55:1611-18
   PubMed Web of Science ®Google Scholar
• Visser ME, Wagener G, Baker BF, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J 2012;33:1142-9
   PubMed Web of Science ®Google Scholar
• Visser ME, Akdim F, Tribble DL, et al. Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res 2010;51:1057-62
   PubMed Web of Science ®Google Scholar
• Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 2012;126(19):2283-92
   PubMed Web of Science ®Google Scholar
• Thomas GS, Cromwell WC, Ali S, et al. Mipomersen, an apolipoprotein b synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2013;62(23):2178-84
   PubMed Web of Science ®Google Scholar
• Vogt A, Parhofer KG. The potential of mipomersen, an ApoB synthesis inhibitor, to reduce necessity for LDL-apheresis in patients with heterozygous familial hypercholesterolemia and coronary artery disease. Expert Opin Pharmacother 2013;14:691-7
   PubMed Web of Science ®Google Scholar
• Sjouke B, Balak DM, Beuers U, et al. Is mipomersen ready for clinical implementation? A transatlantic dilemma. Curr Opin Lipidol 2013;24(4):301-6
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT00694109 [Last accessed 1 June 2014]
   Google Scholar
• Centers for Disease Control and Prevention. Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol—United States, 1999–2002 and 2005 – 2008. MMWR Morb Mortal Wkly Rep 2011;60:109-14
   PubMedGoogle Scholar
• Raal FJ, Giugliano RP, Sabatine MS, et al. Reduction in lipoprotein (a) with the PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of over 1300 patients in 4 phase 2 trials. J Am Coll Cardiol 2014;13):1278-88
   PubMed Web of Science ®Google Scholar
• Stein EA, Honarpour N, Wasserman SM, et al. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 2013;128(19):2113-20
   PubMed Web of Science ®Google Scholar
• Available from: http://www.amgen.com/media/media_pr_detail.jsp?releaseID=1909327 [Last accessed 1 June 2014]
   Google Scholar
• Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375(9719):998-1006
   PubMed Web of Science ®Google Scholar
• Santos RD, Duell PB, East C, et al. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur Heart J 2013. [ Epub ahead of print]
   Web of Science ®Google Scholar